M1069
- Generic Name
- M1069
First in Human Study of M1069 in Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- Metastatic or Locally Advanced Unresectable Solid Tumors
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-11-25
- Target Recruit Count
- 15
- Registration Number
- NCT05198349
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Canada
🇺🇸Sarah Cannon Research Institute (SCRI) (The SCRI Oncology Research Consortium), Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath